Related references
Note: Only part of the references are listed.Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
Ben-Quan Shen et al.
NATURE BIOTECHNOLOGY (2012)
Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR
Stephanie A. Kazane et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody-Drug Conjugates in Rats
C. Andrew Boswell et al.
BIOCONJUGATE CHEMISTRY (2011)
Selective Formation of Covalent Protein Heterodimers with an Unnatural Amino Acid
Benjamin M. Hutchins et al.
CHEMISTRY & BIOLOGY (2011)
Synthesis and Evaluation of Hydrophilic Linkers for Antibody-Maytansinoid Conjugates
Robert Y. Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Site-Specific Coupling and Sterically Controlled Formation of Multimeric Antibody Fab Fragments with Unnatural Amino Acids
Benjamin M. Hutchins et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
Targeting activated integrin alpha v beta 3 with patient-derived antibodies impacts late-stage multiorgan metastasis
Karin Staflin et al.
CLINICAL & EXPERIMENTAL METASTASIS (2010)
Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Jagath R. Junutula et al.
CLINICAL CANCER RESEARCH (2010)
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Nicole M. Okeley et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
An Enhanced System for Unnatural Amino Acid Mutagenesis in E. coli
Travis S. Young et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat et al.
BREAST CANCER RESEARCH (2010)
Comment Re: MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?
Antoinette Hollestelle et al.
CANCER RESEARCH (2009)
MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?
Ann F. Chambers
CANCER RESEARCH (2009)
The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
Stephen C. Alley et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
Novel Peptide Linkers for Highly Potent Antibody-Auristatin Conjugate
Svetlana O. Doronina et al.
BIOCONJUGATE CHEMISTRY (2008)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker
Ezogelin Oflazoglu et al.
CLINICAL CANCER RESEARCH (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
Cell killing by antibody-drug conjugates
Yelena V. Kovtun et al.
CANCER LETTERS (2007)
Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals
Clara P. W. Klerk et al.
BIOTECHNIQUES (2007)
Genetic incorporation of unnatural amino acids into proteins in mammalian cells
Wenshe Liu et al.
NATURE METHODS (2007)
CR011, a fully human monoclonal anti body-auristatin E conjugate, for the treatment of melanoma
KF Tse et al.
CLINICAL CANCER RESEARCH (2006)
Nucleophilic catalysis of oxime ligation
Anouk Dirksen et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2006)
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
SO Doronina et al.
BIOCONJUGATE CHEMISTRY (2006)
Drug-conjugated monoclonal antibodies for the treatment of cancer
JM Lambert
CURRENT OPINION IN PHARMACOLOGY (2005)
Structural characterization of the maytansinoid -: monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry
LT Wang et al.
PROTEIN SCIENCE (2005)
Arming antibodies for cancer therapy
P Polakis
CURRENT OPINION IN PHARMACOLOGY (2005)
Arming antibodies: prospects and challenges for immunoconjugates
AM Wu et al.
NATURE BIOTECHNOLOGY (2005)
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
JF DiJoseph et al.
BLOOD (2004)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study
AW Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Addition of the keto functional group to the genetic code of Escherichia coli
L Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
PR Hamann et al.
BIOCONJUGATE CHEMISTRY (2002)
Synthesis of LJP 993, a multivalent conjugate of the N-terminal domain of β2GPI and suppression of an anti-β92GPI immune response
DS Jones et al.
BIOCONJUGATE CHEMISTRY (2001)
Expanding the genetic code of Escherichia coli
L Wang et al.
SCIENCE (2001)
Share Paper
